Selective
estrogen receptor modulators: Structure, function, and clinical
use [Review].
Osborne,
C. K. and Fuqua, S. A. W. Journal of Clinical Oncology. 18(17):3172-3186,
2000 Sep.
Differences
in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitiveand
-resistant breast carcinomas: preclinical and first clinical investigations.
Naundorf,
H.; Jost-Reuhl, B.; Becker, M.; Reuhl, T.; Neumann, C., and Fichtner,
I. (Reprint available from: Fichtner I Max Delbruck Ctr Mol Med
Robert Rossle Str 10 D-13125 Berlin Germany).. Breast Cancer Research
& Treatment. 60(1):81-92, 2000 Mar.
Development
and characterization of a tamoxifen resistant breast carcinoma
xenograft.
Naundorf,
H.; Becker, M.; Lykkesfeldt, A. E.; Elbe, B.; Neumann, C.; Buttner,
B., and Fichtner, I (Reprint available from: Fichtner I Max Delbruck
Ctr Mol Med Robert Rossle Str 10 D-13092 Berlin Germany).. British
Journal of Cancer. 82(11):1844-1850, 2000 Jun.
Combined
treatment with buserelin and tamoxifen in premenopausal metastatic
breast cancer: A randomized study.
Klijn,
J. G. M.; Beex LVAM; Mauriac, L.; van Zijl, J. A.; Veyret, C.;
Wildiers, J.; Jassem, J.; Piccart, M.; Burghouts, J.; Becquart,
D.; Seynaeve, C.; Mignolet, F., and Duchateau, L. (Reprint available
from: Klijn JGM Dr Daniel den Hoed Klin, Rotterdam Canc Inst,
Dept Med Oncol Groene Hilledijk 301 NL-3075 EA Rotterdam Netherlands).
Journal of the National Cancer Institute. 92(11):903-911, 2000
Jun 7.
Effects
of high dose raloxifene in selected patients with advanced breast
carcinoma.
Gradishar,
W.; Glusman, J.; Lu, Y.; Vogel, C.; Cohen, F. J., and Sledge,
G. W. Cancer. 88(9):2047-2053, 2000 May 1.
Effects
of adjuvant tamoxifen on the endometrium in postmenopausal women
with breast cancer: A prospective long-term study using transvaginal
ultrasound.
Gerber,
B.; Krause, A.; Muller, H.; Reimer, T.; Kulz, T.; Makovitzky,
J.; Kundt, G., and Friese, K. Journal of Clinical Oncology. 18(20):3464-3470,
2000 Oct 15.
Results
of two or five years of adjuvant tamoxifen correlated to steroid
receptor and S-phase levels.
Ferno,
M.; Stal, O.; Baldetrop, B.; Hatschek, T.; Kallstrom, A. C.; Malmstrom,
P.; Nordenskjold, B., and Ryden, S.. Breast Cancer Research &
Treatment. 59(1):69-76, 2000 Jan.
Tamoxifen
adjuvant treatment duration in early breast cancer: Initial results
of a randomized study comparing short-term treatment with long-term
treatment.
Delozier,
T.; Spielmann, M.; Mace-Lesec'h, J.; Janvier, M.; Hill, C.; Asselain,
B.; Julien, J. P.; Weber, B.; Mauriac, L.; Petit, J. C.; Kerbrat,
P.; Malhaire, J. P.; Vennin, P.; Leduc, B., and Namer, M.. Journal
of Clinical Oncology. 18(20):3507-3512, 2000 Oct 15.
Biomarkers
and outcome after tamoxifen treatment in node-positive breast
cancers from elderly women.
Daidone,
M. G.; Luisi, A.; Martelli, G.; Benini, E.; Veneroni, S.; Tomasic,
G.; De Palo G, and Silvestrini, R. (Reprint available from: Daidone
MG Ist Nazl Studio & Cura Tumori Via Venezian 1 I-20133 Milan
Italy). British Journal of Cancer. 82(2):270-277, 2000 Jan.
Effect
of adjuvant tamoxifen on the endometrium in women with breast
cancer: A prospective study using office endometrial biopsy.
Barakat,
R. R.; Gilewski, T. A.; Almadrones, L.; Saigo, P. E.; Venkatraman,
E.; Hudis, C., and Hoskins, W. J. Journal of Clinical Oncology.
18(20):3459-3463, 2000 Oct 15.
Surveillance
for uterine abnormalities in tamoxifen-treated breast carcinoma
survivors - A community-based study.
Althuis,
M. D.; Sexton, M.; Langenberg, P.; Bush, T. L.; Tkaczuk, K.; Magaziner,
J., and Khoo, L. Cancer. 89(4):800-810, 2000 Aug 15.
Similarities
and distinctions in the mode of action of different classes of
antioestrogens [Review].
Wakeling,
A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract
Approaches
targeted to estrogen receptors for treatment of tamoxifen-resistant
breast cancer: A brief overview.
Terakawa, N. (Reprint available from: Terakawa N Tottori Univ,
Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan)..
Oncology. 59(Suppl 1):3-4, 2000. No abstract
Preliminary
assessment of cognitive function in breast cancer patients treated
with tamoxifen.
Paganini-Hill,
A. and Clark, L. J. Breast Cancer Res.earch & Treatment. 64(2):165-176,
2000 Nov.
Symposium
overview: Estrogens and antiestrogens in managing the patient
with breast cancer.
Newman,
L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and
Singletary, S. E. (Reprint available from: Singletary SE Univ
Texas, MD Anderson Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box
106 Houston, TX 77030 USA).. Annals of Surgical Oncology. 7(8):568-574,
2000 Sep. In process
The
ovary: cysts, screening, and tamoxifen.
Mourits,
M. J. E.; van der Zee, A. G. J.; Willemse, P. H. B., and de Vries,
E. G. E. (Reprint available from: de Vries EGE Univ Groningen
Hosp, Dept Med Oncol POB 30 001 NL-9700 RB Groningen Netherlands).
Lancet. 355(9220):2078-2079, 2000 Jun 10.
Concentrations
of tamoxifen and its major metabolites in hormone
responsive and resistant breast tumours.
MacCallum, J.; Cummings, J.; Dixon, J. M., and Miller, W.
R. (Reprint available from: MacCallum J Napier Univ, Dept Life
Sci Merchiston Campus,Colinton Rd Edinburgh EH10 5DT Midlothian
Scotland).. British Journal of Cancer. 82(10):1629-1635, 2000
May.
How
is tamoxifen's action subverted?
Jordan, V. C. (Reprint available from: Jordan VC Northwestern
Univ, Sch Med, Rober H Lurie Comprehens Canc Ctr 303 E Chicago
Ave,Olson Pavil 8258 Chicago, IL 60611 USA). Journal of the National
Cancer Institute. 92(2):92-94, 2000 Jan 19. No abstract
Serum
lipid levels during and after adjuvant toremifene or tamoxifen
therapy for breast cancer.
Joensuu, H.; Holli, K.; Oksanen, H., and Valavaara, R. (Reprint
available from: Joensuu H Univ Helsinki, Cent Hosp, Dept Oncol
Haartmaninkatu 4,POB 180 FIN-00029 Helsinki Finland). Breast Cancer
Research & Treatment. 63(3):225-234, 2000 Oct. In process
One
step forward or one step back with tamoxifen?
Gelmon, K. (Reprint available from: Gelmon K British Columbia
Canc Agcy Vancouver BC V5Z 4E6 Canada). Lancet. 356(9233):868-869,
2000 Sep 9. No abstract
Endometrial
protection from tamoxifen-stimulated changes by a evonorgestrel-releasing
intrauterine system: a randomised controlled trial.
Gardner, F. J. E.; Konje, J. C.; Abrams, K. R.; Brown, L.
J. R.; Khanna, S.; Al-Azzawi, F.; Bell, S. C., and Taylor, D.
J.. Lancet. 356(9243):1711-1717, 2000 Nov 18. No abstract
Combined
endocrine therapy for breast cancer - New life for an old idea?
Davidson, N. E. (Reprint available from: Davidson NE Johns
Hopkins Oncol Ctr 1650 Orleans St, Rm 409 Baltimore, MD 21231
USA). Journal of the National Cancer Institute. 92(11):859-860,
2000 Jun 7. No abstract
Risk
and prognosis of endometrial cancer after tamoxifen for breast
cancer.
Bergman, L.; Beelen, M. L. R.; Gallee, M. P. W.; Hollema,
H.; Benraadt, J., and van LeeuwenF. E.. Lancet. 356(9233):881-887,
2000 Sep 9. IN PROCESS
